Label: SYNTOCINON- oxytocin injection, solution 

  • Label RSS
  • NDC Code(s): 0078-0060-04
  • Packager: Sandoz Pharmaceuticals Corporation
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status:

Drug Label Information

Updated 07/06

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION

    Syntocinon®

    (oxytocin) injection, USP

    Caution: Federal law prohibits dispensing without prescription.

    Close
  • DESCRIPTION

    Syntocinon® (oxytocin) is a synthetic, (1-6) cyclic nonapeptide. Chemically, oxytocin is designated as Glycinamide, L-cysteinyl-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl- L-leucy1-, cyclic (1-6)-disulfide.

    The structural formula is:

    Image from Drug Label Content

    Syntocinon® (oxytocin) injection is provided as a sterile solution for intravenous or intramuscular administration. Each 1 mL of solution contains 10 USP or International Units of oxytocin and the following inactive ingredients:

    acetic acid, NF, qs to ....................... pH 4 ± 0.3

    alcohol, USP............................ 0.61 % by vol.

    chlorobutanol, NF ..........,................... 0.5%

    sodium acetate, USP ...,........................ 1 mg

    sodium chloride, USP ........................ 0.017 mg

    water for injection, USP, qs to ..................... 1 mL

    Close
  • CLINICAL PHARMACOLOGY

    The pharmacologic and clinical properties of Syntocinon® (oxytocin) are identical with the naturally occurring oxytocic principle of the posterior lobe of the pituitary. Syntocinon® (oxytocin) injection does not contain the amino acids characteristic of vasopressin, and therefore has fewer and less severe cardiovascular effects. Syntocinon® (oxytocin) exerts a selective action on the smooth musculature of the uterus, particularly toward the end of pregnancy, during labor and immediately following delivery. Oxytocin stimulates rhythmic contractions of the uterus, increases the frequency of existing contractions, and raises the tone of the uterine musculature.

    Syntocinon® (oxytocin), when given in appropriate doses during pregnancy, is capable of eliciting graded increases in uterine motility from a moderate increase in the rate and force of spontaneous motor activity to sustained tetanic contraction.

    Syntocinon® (oxytocin) is promptly effective after parenteral administration. Following intramuscular injection, the myotonic effect on the uterus appears in 3-7 minutes, and persists for 30-60 minutes. With intravenous injection, the uterine effect appears within 1 minute and is of more brief duration.

    Close
  • INDICATIONS AND USAGE

    Important Notice

    Syntocinon® (oxytocin) injection is indicated for the medical rather than the elective induction of labor. Available data and information are inadequate to define the benefits to risk considerations in the use of the drug product for elective induction. Elective induction of labor is defined as the initiation of labor for convenience in an individual with a term pregnancy who is free of medical indications.

    Antepartum

    Syntocinon® (oxytocin) is indicated for the initiation or improvement of uterine contractions, where this is desirable and considered suitable, in order to achieve early vaginal delivery for fetal or maternal reasons. It is indicated for (1) induction of labor in patients with a medical indication for the initiation of labor, such as Rh problems, maternal diabetes, pre-eclampsia at or near term, when delivery is in the best interest of mother and fetus or when membranes are prematurely ruptured and delivery is indicated; (2) stimulation or reinforcement of labor, as in selected cases of uterine inertia; (3) as adjunctive therapy in the management of incomplete or inevitable abortion. In the first trimester, curettage is generally considered primary therapy. In the second trimester abortion, oxytocin infusion will often be successful in emptying the uterus. Other means of therapy, however, may be required in such cases.

    Postpartum

    Syntocinon® (oxytocin) injection is indicated to produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage.

    Close
  • CONTRAINDICATIONS

    Syntocinon® (oxytocin) injection is contraindicated in any of the following conditions: Significant cephalopelvic disproportion; unfavorable fetal positions or presentations which are undeliverable without conversion prior to delivery (transverse lies); i.e., in obstetrical emergencies where the benefit-to-risk ratio for either the fetus or the mother favors surgical intervention; in cases of fetal distress where delivery is not imminent; prolonged use in uterine inertia or severe toxemia; hypertonic uterine patterns; patients with hypersensitivity to the drug; induction or augmentation of labor in those cases where vaginal delivery is contraindicated, such as cord presentation or prolapse, total placental previa, and vasa previa.

    Close
  • WARNINGS

    Syntocinon® (oxytocin), when given for induction or stimulation of labor, must be administered only by the intravenous route and with adequate medical supervision in a hospital.

    Close
  • PRECAUTIONS

    General

    All patients receiving intravenous oxytocin must he under continuous observation by trained personnel with a thorough knowledge of the drug and qualified to identify complications. A physician qualified to manage any complications should be immediately available.

    When properly administered, oxytocin should stimulate uterine contractions similar to those seen in normal labor. Overstimulation of the uterus by improper administration can be hazardous to both mother and fetus. Even with proper administration and adequate supervision, hypertonic contractions can occur in patients whose uteri are hypersensitive to oxytocin.

    Except in unusual circumstances, oxytocin should not be administered in the following conditions: prematurity, borderline cephalopelvic disproportion, previous major surgery on the cervix or uterus including cesarean section, over-distention of the uterus, grand multiparity, or invasive cervical carcinoma. Because of the variability of the combinations of factors which may be present in the conditions listed above, the definition of “unusual circumstances” must be left to the judgment of the physician. The decision can only be made by carefully weighing the potential benefits which oxytocin can provide in a given case against rare but definite potential for the drug to produce hypertonicity or tetanic spasm.

    Maternal deaths due to hypertensive episodes, subarachnoid hemorrhage, rupture of the uterus, and fetal deaths due to various causes have been reported associated with the use of parenteral oxytocic drugs for induction of labor or for augmentation in the first and second stages of labor.

    Oxytocin has been shown to have an intrinsic antidiuretic effect, acting to increase water reabsorption from the glomerular filtrate. Consideration should, therefore, be given to the possibility of water intoxication, particularly when oxytocin is administered continuously by infusion and the patient is receiving fluids by mouth.

    Drug Interactions

    Severe hypertension has been reported when oxytocin was given 3-4 hours following prophylactic administration of a vasoconstrictor in conjunction with caudal block anesthesia. Cyclopropane anesthesia may modify oxytocin's cardiovascular effects, so as to produce unexpected results such as hypotension. Maternal sinus bradycardia with abnormal atrioventricular rhythms has also been noted when oxytocin was used concomitantly with cyclopropane anesthesia.

    Carcinogenesis, Mutagenesis, Impairment of Fertility

    There are no animal or human studies on the carcinogenicity and mutagenicity of this drug, nor is there any information on its effect on fertility.

    Pregnancy

    Teratogenic Effects:

    Animal reproduction studies have not been conducted with oxytocin. There are no known indications for use in the first trimester of pregnancy other than in relation to spontaneous or induced abortion. Based on the wide experience with this drug and its chemical structure and pharmacological properties, it would not be expected to present a risk of fetal abnormalities when used as indicated.

    Nonteratogenic Effects:

    See ADVERSE REACTIONS in the fetus or infant.

    Labor and Delivery

    See INDICATIONS AND USAGE.

    Nursing Mothers

    Syntocinon® (oxytocin) may be found in small quantities in mother's milk. If a patient requires the drug postpartum to control severe bleeding, she should not commence nursing until the day after Syntocinon® (oxytocin) has been discontinued.

    Pediatric Use

    Safety and effectiveness in pediatric patients have not been established.

    Close
  • ADVERSE REACTIONS

    The following adverse reactions have been reported in the mother: Anaphylactic reaction, Postpartum hemorrhage, Cardiac arrhythmia, Fatal afibrinogenemia, Nausea, Vomiting, Premature ventricular contractions, and Pelvic hematoma.

    Excessive dosage or hypersensitivity to the drug may result in uterine hypertonicity, spasm, tetanic contraction, or rupture of the uterus.

    The possibility of increased blood loss and afibrinogenemia should be kept in mind when administering the drug.

    Severe water intoxication with convulsions and coma has occurred, associated with a slow oxytocin infusion over a 24-hour period. Maternal death due to oxytocin-induced water intoxication has been reported.

    The following adverse reactions have been reported in the fetus or infant:

    Due to induced uterine motility: Bradycardia, Premature ventricular contractions and other arrhythmias, Permanent CNS or brain damage, and Fetal death.

    Due to use of oxytocin in the mother: Low Apgar scores at 5 minutes. Neonatal jaundice, and Neonatal retinal hemorrhage.

    Close
  • DRUG ABUSE AND DEPENDENCE

    There is no evidence that Syntocinon® (oxytocin) has been abused or has provoked drug dependence.

    Close
  • OVERDOSAGE

    Overdosage with oxytocin depends essentially on uterine hyperactivity, whether or not due to hypersensitivity to this agent. Hyperstimulation with strong (hypertonic) or prolonged (tetanic) contractions, or a resting tone of 15-20 mm H2O or more between contractions can lead to tumultuous labor, uterine rupture, cervical and vaginal lacerations, postpartum hemorrhage, uteroplacental hypoperfusion, and variable deceleration of fetal heart, fetal hypoxia, hypercapnia, or death. Water intoxication with convulsions, which is caused by the inherent antidiuretic effect of oxytocin, is a serious complication that may occur if large doses (40-50 mL/minute) are infused for long periods. Treatment of water intoxication consists of discontinuation of oxytocin, restriction of fluid intake, diuresis, IV hypertonic saline solution, correction of electrolyte imbalance, control of convulsions with judicious use of a barbiturate, and special nursing care for the comatose patient.

    Close
  • DOSAGE AND ADMINISTRATION

    Dosage of oxytocin is determined by uterine response. The following dosage information is based upon the various regimens and indications in general use. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, wherever solution and container permit.

    A. Induction of Stimulation of Labor

    Intravenous infusion (drip method) is the only acceptable method of administration for the induction or stimulation of labor.

    Accurate control of the rate of infusion flow is essential. An infusion pump or other such device and frequent monitoring of strength of contractions and fetal heart rate are necessary for the safe administration of oxytocin for the induction or stimulation of labor. If uterine contractions become too powerful, the infusion can be abruptly stopped, and oxytocin stimulation of the uterine musculature will soon wane.

    1. An intravenous infusion of non-oxytocin containing solution should be started. Physiologic electrolyte solution should be used except under unusual circumstances.
    2. To prepare the usual solution for infusion, the contents of one 1-mL ampul are combined aseptically with 1,000 mL of non-hydrating diluent. The combined solution, rotated in the infusion bottle to insure thorough mixing, contains 10 mU/mL. Add the container with dilute oxytocin solution to the system through use of a constant infusion pump or other such device, to control accurately the rate of infusion.
    3. The initial dose should be no more than 1-2 mU/minute. The dose may be gradually increased in increments of no more than 1-2 mU/minute, until a contraction pattern has been established which is similar to norma1 labor.
    4. The fetal heart rate, resting uterine tone, and the frequency, duration, and force of contractions should be monitored.
    5. The oxytocin infusion should be discontinued immediately in the event of uterine hyperactivity or fetal distress. Oxygen should be administered to the mother. The mother and the fetus must be evaluated by the responsible physician.

    B. Control of Postpartum Uterine Bleeding

    1. Intravenous Infusion (Drip Method): To control postpartum bleeding, 10-40 units of oxytocin may be added to 1,000 mL of a non-hydrating diluent and run at a rate necessary to control uterine atony.
    2. Intramuscular Administration: 1 mL (10 units) of oxytocin can be given after delivery of the placenta.

    C. Treatment of Incomplete or Inevitable Abortion

    Intravenous infusion with physiologic saline solution, 500 mL, or 5% dextrose in physiologic saline solution to which 10 units of Syntocinon® (oxytocin) have been added should be infused at a rate of 20-40 drops/minute.

    Close
  • HOW SUPPLIED

    Syntocinon® (oxytocin) injection, USP

    Available as a 1 mL sterile ampul containing 10 USP or International Units of oxytocin. SandoPak® unit dose packages of 50 ampuls (NDC 0078-0060-04).

    Store and dispense

    Below 77ºF (25ºC); DO NOT FREEZE.

    Sandoz Pharmaceuticals Corporation East Hanover, New Jersey 07936

    REV: MAY 1996                                30288904

    Close
  • INGREDIENTS AND APPEARANCE
    SYNTOCINON 
    syntocinon injection, solution
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0078-0060
    Route of Administration INTRAMUSCULAR, INTRAVENOUS DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    oxytocin (oxytocin) 10 [iU]  in 1 mL
    Inactive Ingredients
    Ingredient Name Strength
    acetic acid  
    alcohol  
    chlorobutanol  
    sodium acetate 1 mg  in 1 mL
    sodium chloride 0.017 mg  in 1 mL
    water  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0078-0060-04 50 in 1 PACKAGE
    1 1 mL in 1 AMPULE
    Labeler - Sandoz Pharmaceuticals Corporation
    Close